SLC16A1 and cancer: Several studies have associated increased monocarboxylate transporter 1 (MCT1) expression in various cancers with chemoresistance and poor prognosis (Sant et al., 2009; Leu et al., 2021; Chen et al., 2010; Chen et al., 2019a; Simões-Sousa et al., 2016; Pinheiro et al., 2008; Miranda-Gonçalves et al., 2021; Latif et al., 2017; Sandforth et al., 2020).